Late causes of death after pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol. 2016;68:487 98. S10.8-45. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132:2118 25. S10.8-46. Nieminen HP, Jokinen EV, Sairanen HI, Causes of late deaths after pediatric cardiac surgery: a population-based study. J Am Coll Cardiol. 2007;50:1263 71. S10.8-47. Zomer AC, Vaartjes I, Uiterwaal CS, et al. Circumstances of death in adult congenital heart disease. Int J Cardiol. 2012;154:168 72. S10.8-48. Lange R, Horer J, Kostolny M, et al. Presence of a ventricular septal defect and the Mustard operation are risk factors for late mortality after the atrial switch operation: thirty years of follow-up in 417 patients at a single center. Circulation. 2006;114:1905 13. S10.8-49. Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfusion and function of the systemic right ventricle in patients after atrial switch procedure for complete transposition: long-term follow-up. J Am Coll Cardiol. 2000;36:1365 70. S10.8-50. Millane T, Bernard EJ, Jaeggi E, et al. Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposi- tion of the great arteries. J Am Coll Cardiol. 2000;35:1661 8. S10.8-51. Schwerzmann M, Salehian O, Harris L, et al. Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposi- tion of the great arteries. Eur Heart J. 2009;30:1873 9. S10.8-52. Buber J, Ackley TJ, Daniels CJ, et al. Outcomes following the implantation of cardioverter-defibrillator for primary prevention in transposition of the great arteries after intra-atrial baffle repair: a single-centre experience. Europace. 2016;18:1016 22. S10.8-53. Backhoff D, Kerst G, Peters A, et al. Internal cardioverter defibril- lator indications and therapies after atrial baffle procedure for d-transposition of the great arteries: a multicenter analysis. Pacing Clin Electrophysiol. 2016;39:1070 6. S10.8-54. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000;86:1111 6. S10.8-55. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J. 2010;31:1220 9. S10.8-56. Silka MJ, Hardy BG, Menashe VD, et al. A population-based pro- spective evaluation of risk of sudden cardiac death after opera- tion for common congenital heart defects. J Am Coll Cardiol. 1998;32:245 51. S10.8-57. Abou Hassan OK, Fahed AC, Batrawi M, et al. NKX2-5 mutations in an inbred consanguineous population: genetic and phenotypic diversity. Sci Rep. 2015;5:8848. S10.8-58. El Malti R, Liu H, Doray B, et al. A systematic variant screening in familial cases of congenital heart defects demonstrates the use- fulness of molecular genetics in this field. Eur J Human Genet. 2016;24:228 36. S10.8-59. Ellesoe SG, Johansen MM, Bjerre JV, et al. Familial atrial septal defect and sudden cardiac death: identification of a novel NKX2-5 mutation and a review of the literature. Congenit Heart Dis. 2016;11:283 90. S10.8-60. Cuypers JA, Opic P, Menting ME, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow up after surgical closure at young age. Heart. 2013;99:1346 52. CLINICAL STATEMENTS AND GUIDELINES S10.8-61. Kuijpers JM, van der Bom T, van Riel AC, et al. Secundum atrial septal defect is associated with reduced survival in adult men. Eur Heart J. 2015;36:2079 86. S10.8-62. Verheugt CL, Uiterwaal CS, Grobbee DE, et al. Long-term progno- sis of congenital heart defects: a systematic review. Int J Cardiol. 2008;131:25 32. S10.8-63. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J. 2005;26:2325 33. S10.8-64. Arya S, Kovach J, Singh H, et al. Arrhythmias and sudden death among older children and young adults following tetralogy of Fallot repair in the current era: are previously reported risk factors still applicable? Congenit Heart Dis. 2014;9:407 14. S10.8-65. Wu MH, Lu CW, Chen HC, et al. Arrhythmic burdens in patients with tetralogy of Fallot: a national database study. Heart Rhythm. 2015;12:604 9. S10.8-66. Baraona F, Valente AM, Porayette P, et al. Coronary arteries in child- hood heart disease: implications for management of young adults. J Clin Exp Cardiolog. suppl 8 2012 006. S10.8-67. Naimo PS, Fricke TA, Yong MS, et al. Outcomes of truncus arteriosus repair in children: 35 years of experience from a single institution. Semin Thorac Cardiovasc Surg. 2016;28:500 11. S10.8-68. Pundi KN, Pundi KN, Johnson JN, et al. Sudden cardiac death and late arrhythmias after the Fontan operation. Congenit Heart Dis. 2017;12:17 23. 11. DEFIBRILLATORS OTHER THAN TRANSVENOUS ICDS 11.1. Subcutaneous Implantable Cardioverter-Defibrillator S11.1-1. Bardy GH, Smith WM, Hood MA, et al. An entirely subcuta- neous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36 44. S11.1-2. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944 53. S11.1-3. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657 65. S11.1-4. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65:1605 15. S11.1-5. El-Chami MF, Levy M, Kelli HM, et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol. 2015;26:900 4. S11.1-6. de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart. 2013;99:1018 23. S11.1-7. Olde Nordkamp LR, Dabiri AL, Boersma LV, et al. The entirely subcu- taneous implantable cardioverter-defibrillator: initial clinical experi- ence in a large Dutch cohort. J Am Coll Cardiol. 2012;60:1933 9. S11.1-8. K be J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter- defibrillators: a multicenter case-control study. Heart Rhythm. 2013;10:29 36. S11.1-9. Groh CA, Sharma S, Pelchovitz DJ, et al. Use of an electrocar- diographic screening tool to determine candidacy for a subcu- taneous implantable cardioverter-defibrillator. Heart Rhythm. 2014;11:1361 6. S11.1-10. Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and pre- dictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25:494 9. S11.1-11. Randles DA, Hawkins NM, Shaw M, et al. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace. 2014;16:1015 21. S11.1-12. Al-Khatib SM, Greiner MA, Peterson ED, et al. Patient and implant- ing physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002 2005. Circ Arrhythm Electrophysiol. 2008;1:240 9. S11.1-13. Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrilla- tor therapy. Am Heart J. 2012;163:753 60. 11.2. Wearable Cardioverter-Defibrillator S11.2-1. Chung MK, The role of the wearable cardioverter defibrillator in clinical practice. Cardiol Clin. 2014;32:253 70. S11.2-2. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56:194 203. S11.2-3. Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wear- able cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. 2010;33:353 67. S11.2-4. Piccini JP Sr, Allen LA, Kudenchuk PJ, et al. Wearable cardioverter- defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016;133:1715 27. S11.2-5. Ellenbogen KA, Koneru JN, Sharma PS, et al. Benefit of the wear- able cardioverter-defibrillator in protecting patients after implant- able-cardioverter defibrillator explant. Results from the National Registry. JACC Clin Electrophysiol. 2017;3:243 50. S11.2-6. LifeVest Wearable Cardioverter Defibrillator. Available at: http:// www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm458494.htm. Accessed August 26, 2016. 11.3. Automated External Defibrillator S11.3-1. Marenco JP, Wang PJ, Link MS, et al. Improving survival from sud- den cardiac arrest: the role of the automated external defibrillator. JAMA. 2001;285:1193 200. S11.3-2. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recommen- dations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437 5 S11.3-3. Blom MT, Beesems SG, Homma PC, et al. Improved survival after out-of-hospital cardiac arrest and use of automated external defi- brillators. Circulation. 2014;130:1868 75. S11.3-4. Koster RW, Automatic external defibrillator: key link in the chain of survival. J Cardiovasc Electrophysiol. 2002;13:S92 5. S11.3-5. Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrilla- tion by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206 9. S11.3-6. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated external defibrillators. N Engl J Med. 2002;347:1242 7. S11.3-7. Page RL, Joglar JA, Kowal RC, et al. Use of automated external defi- brillators by a US airline. N Engl J Med. 2000;343:1210 6. S11.3-8. Page RL, Husain S, White LY, et al. Cardiac arrest at exercise facilities: implications for placement of automated external defibrillators. J Am Coll Cardiol. 2013;62:2102 9. S11.3-9. Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consor- tium population of 21 million. J Am Coll Cardiol. 2010;55:1713 20. S11.3-10. Hansen CM, Lippert FK, Wissenberg M, et al. Temporal trends in coverage of historical cardiac arrests using a volunteer-based net- work of automated external defibrillators accessible to laypersons and emergency dispatch centers. Circulation. 2014;130:1859 67. S11.3-11. Weisfeldt ML, Everson-Stewart S, Sitlani C, et al. Ventricular tachyar- rhythmias after cardiac arrest in public versus at home. N Engl J Med. 2011;364:313 21. S11.3-12. Bardy GH, Lee KL, Mark DB, et al. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med. 2008;358:1793 804. S11.3-13. Travers AH, Perkins GD, Berg RA, et al. Part 3: adult basic life sup- port and automated external defibrillation: 2015 International CLINICAL STATEMENTS AND GUIDELINES Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132:S51 83. 12. SPECIAL CONSIDERATIONS FOR CATHETER ABLATION S12-1. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4:253 62. S12-2. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004;15:52 8. S12-3. Mehdirad AA, Keim S, Rist K, et al. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. Pacing Clin Electrophysiol. 1995;18:2135 43. S12-4. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla- tion of ventricular tachycardia in dilated nonischemic cardiomy- opathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) study. Circulation. 2014;129:728 36. S12-5. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroana- tomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21:47 53. S12-6. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricu- lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674 83. S12-7. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic reso- nance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977 85. S12-8. Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced mag- netic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138 45. S12-9. Roberts WC, Siegel RJ, McManus BM, Idiopathic dilated car- diomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340 55. S12-10. Piers SR, Tao Q, van Huls van Taxis C.F.B, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S12-11. Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol. 2010;55:2366 72. S12-12. Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol. 2011;4:653 9. 13. POSTMORTEM EVALUATION OF SCD S13-1. Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investiga- tion of sudden cardiac death. Virchows Arch. 2008;452:11 8. S13-2. de Noronha SV, Behr ER, Papadakis M, et al. The importance of specialist cardiac histopathological examination in the investigation of young sudden cardiac deaths. Europace. 2014;16:899 907. S13-3. Wilde AA, Behr ER. Genetic testing for inherited cardiac disease. Nature reviews. Cardiology. 2013;10:571 83. S13-4. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy- negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin. Proc. 2012;87:524 39. S13-5. Tang Y, Stahl-Herz J, Sampson BA. Molecular diagnostics of cardio- vascular diseases in sudden unexplained death. Cardiovasc Pathol. 2014;23:1 4. S13-6. Bagnall RD, Das KJ, Duflou J, et al. Exome analysis-based molecular autopsy in cases of sudden unexplained death in the young. Heart Rhythm. 2014;11:655 62. S13-7. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441 52. S13-8. Semsarian C, Ingles J. Molecular autopsy in victims of inherited arrhythmias. J Arrhythm. 2016;32:359 65. S13-9. Vassalini M, Verzeletti A, Restori M, et al. An autopsy study of sud- den cardiac death in persons aged 1 40 years in Brescia (Italy). J Cardiovasc Med. 2016;17:446 53. S13-10. Wu Q, Zhang L, Zheng J, et al. Forensic pathological study of 1656 cases of sudden cardiac death in southern. China Medicine. 2016;95:e2707. S13-11. Giudici V, Spanaki A, Hendry J, et al. Sudden arrhythmic death syndrome: diagnostic yield of comprehensive clinical evalua- tion of pediatric first-degree relatives. Pacing Clin Electrophysiol. 2014;37:1681 5. S13-12. Steinberg C, Padfield GJ, Champagne J, et al. Cardiac abnormali- ties in first-degree relatives of unexplained cardiac arrest victims: a report from the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry. Circ Arrhythm Electrophysiol. 2016;9:e004274. S13-13. Wong LC, Roses-Noguer F, Till JA, et al. Cardiac evaluation of pedi- atric relatives in sudden arrhythmic death syndrome: a 2-center experience. Circ Arrhythm Electrophysiol. 2014;7:800 6. S13-14. van der Werf C, Stiekema L, Tan HL, et al. Low rate of cardiac events in first-degree relatives of diagnosis-negative young sudden unex- plained death syndrome victims during follow-up. Heart Rhythm. 2014;11:1728 32. S13-15. Papadakis M, Raju H, Behr ER, et al. Sudden cardiac death with autopsy findings of uncertain significance: potential for erroneous interpretation. Circ Arrhythm Electrophysiol. 2013;6:588 96. S13-16. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con- sensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932 63. 14. TERMINAL CARE S14-1. Berger JT, Gorski M, Cohen T. Advance health planning and treat- ment preferences among recipients of implantable cardioverter defibrillators: an exploratory study. J Clin Ethics. 2006;17:72 8. S14-2. Lewis KB, Stacey D, Matlock DD. Making decisions about implant- able cardioverter-defibrillators from implantation to end of life: an integrative review of patients perspectives. Patient. 2014;7:243 60. S14-3. Hill L, McIlfatrick S, Taylor B, et al. Patients perception of implant- able cardioverter defibrillator deactivation at the end of life. Palliat Med. 2015;29:310 23. S14-4. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi- cian communication, and the implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571 7. S14-5. Matlock DD, Nowels CT, Masoudi FA, et al. Patient and cardiolo- gist perceptions on decision making for implantable cardioverter- defibrillators: a qualitative study. Pacing Clin Electrophysiol. 2011;34:1634 4. S14-6. Buchhalter LC, Ottenberg AL, Webster TL, et al. Features and out- comes of patients who underwent cardiac device deactivation. JAMA Intern Med. 2014;174:80 5. S14-7. Dodson JA, Fried TR, Van Ness PH, et al. Patient preferences for deactivation of implantable cardioverter-defibrillators. JAMA Intern Med. 2013;173:377 9. S14-8. Goldstein NE, Lampert R, Bradley E, et al. Management of implant- able cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004;141:835 8. S14-9. Goldstein N, Carlson M, Livote E, et al. Brief communication: man- agement of implantable cardioverter-defibrillators in hospice: a nationwide survey. Ann Intern Med. 2010;152:296 9. S14-10. Kirkpatrick JN, Gottlieb M, Sehgal P, et al. Deactivation of implant- able cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol. 2012;109:91 4. S14-11. Kelley AS, Reid MC, Miller DH, et al. Implantable cardioverter-defi- brillator deactivation at the end of life: a physician survey. Am Heart J. 2009;157:702 8. CLINICAL STATEMENTS AND GUIDELINES S14-12. Kramer DB, Kesselheim AS, Brock DW, et al. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm. 2010;7:1537 42. S14-13. Mueller PS, Jenkins SM, Bramstedt KA, et al. Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes. Pacing Clin Electrophysiol. 2008;31:560 8. 15. SHARED DECISION-MAKING S15-1. Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an integrative review of patients perspectives. Patient. 2014;7:243 60. S15-2. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010;16:106 13. S15-3. Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi- cian communication, and the implantable cardioverter-defibrillator. JAMA Intern Med. 2013;173:571 7. S15-4. Ottenberg AL, Mueller PS, Topazian RJ, et al. It s not broke, so let s not try to fix it : why patients decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol. 2014;37:1306 14. S15-5. Yuhas J, Mattocks K, Gravelin L, et al. Patients attitudes and per- ceptions of implantable cardioverter-defibrillators: potential barri- ers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012;35:1179 87. S15-6. Vig EK, Pearlman RA. Good and bad dying from the perspective of terminally ill men. Arch Intern Med. 2004;164:977 81. S15-7. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681 92. S15-8. Quill TE, Brody H. Physician recommendations and patient auton- omy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125:763 9. 16. COST AND VALUE CONSIDERATIONS S16-1. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S16-2. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effective- ness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316:1093 103. S16-3. Mushlin AI, Hall J, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators. Results from MADIT. Circulation. 1998;97:2129 35. S16-4. O Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator. Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416 21. S16-5. Larson G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic Analysis Substudy. Circulation. 2002;105:2049 57. S16-6. Zwanziger J, Hall WJ, Dick AW, et al. The cost-effectiveness of implantable cardioverter-defibrillators. Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310 8. S16-7. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi- brillator therapy or amiodarone in chronic stable heart failure. Results from the Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT). Circulation. 2006;114:135 42. S16-8. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost- effectiveness of implantable cardioverter defibrillators in the treat- ment of ventricular arrhythmias among Medicare beneficiaries. Am J Med. 2002;112:519 27. S16-9. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco- nomic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593 600. S16-10. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii iv, ix xi, 1 164. S16-11. Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of implant- able cardioverter-defibrillators. N Engl J Med. 2005;353:1471 80. S16-12. Smith T, Jordaens L, Theuns D.A.M.J, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: A European analysis. Eur Heart J. 2013;34:211 9. S16-13. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec- tiveness of prophylactic implantation of cardioverter defibril- lator in patients with reduced left ventricular systolic function: Results of Markov modelling in a European population. Europace. 2008;11:716 26. S16-14. Goldenberg I, Moss AJ, Maron BJ, et al. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10 suppl:67 83. S16-15. Bigger JT, Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569 75. S16-16. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarc- tion. N Engl J Med. 2004;351:2481 8. S16-17. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427 36. S16-18. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071 8. S16-19. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratifi- cation on cost-effectiveness of the implantable cardioverter defibril- lator. Am Heart J. 2002;144:440 8. S16-20. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147:251 62. 17. QUALITY OF LIFE S17-1. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibril- lator therapy or amiodarone in heart failure. N Engl J Med. 2008;359:999 1008. S17-2. Noyes K, Corona E, Veazie P, et al. Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. American journal of cardiovascular drugs: drugs, devices, and other interventions. 2009;9:393 400. S17-3. Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defi- brillators and quality of life: results from the defibrillators in non- ischemic cardiomyopathy treatment evaluation study. Archives of internal medicine. 2007;167:2226 32. CLINICAL STATEMENTS AND GUIDELINES Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (October 2017) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* Sana M. Al-Khatib, Chair Duke Clinical Research Institute; Duke University Professor of Medicine None None None None None None None William G. Stevenson, Vice Chair Vanderbilt University Medical Center Professor; Brigham and Women s Hospital Director of Clinical Cardiac EP St. Jude Medical Boston Scientific Biosense Webster Michael J. Ackerman Mayo Clinic Professor of Medicine, Pediatrics, and Pharmacology; Long QT Syndrome/Genetic Heart Rhythm Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory Director Audentes Therapeutics Boston Scientific Gilead Sciences Invitae Medtronic MyoKardia St. Jude Medical None None None Transgenomic (Familion) Blue Ox Health Corporation AliveCor StemoniX William J. Bryant Dominick Feld Hyde Attorney at Law None None None None None None None David J. Callans University of Pennsylvania Health System Professor of Medicine; Associate Director of EP Biosense Webster Biotronik Boston Scientific Medtronic St. Jude Medical None None Biosense Webster (PI) Endosense (PI) Anne B. Curtis University at Buffalo SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair Medtronic St. Jude Medical Barbara J. Deal Getz Professor of Cardiology Feinberg School of Medicine Northwestern University None None None None None None None Timm Dickfeld University of Maryland Associate Professor of Medicine Biosense St. Jude Medical Siemens None None Biosense General Electric Impulse Dynamics Siemens Anne M. Gillis University of Calgary Professor of Medicine None None None Christopher B. Granger Duke Clinical Research Institute; Duke University Professor of Medicine; Director, Cardiac Care Unit AstraZeneca Gilead Sciences GlaxoSmithKline Janssen Pharmaceuticals Medtronic Pfizer Sanofi-aventis None None AstraZeneca GlaxoSmithKline Janssen Pharmaceuticals Medtronic Pfizer Sanofi-aventis GE Healthcare Medtronic ZOLL Medical Spacelabs Phillips Stephen C. Hammill Mayo Clinic Professor Emeritus of Medicine None None None None None None None Mark A. Hlatky Stanford University School of Medicine Professor of Health and Research Policy, and of Cardiovascular Medicine None None None None None None None Jos A. Joglar UT Southwestern Medical Center Professor of Internal Medicine; Clinical Cardiac EP Fellowship Program Director None None None None None None None G. Neal Kay University of Alabama at Birmingham Professor Emeritus None None None None None None None Michael E. Field University of Wisconsin School of Medicine and Public Health Director, Clinical EP and Cardiac Arrhythmia Service, Associate Professor of Medicine None None None None None None None (Continued) CLINICAL STATEMENTS AND GUIDELINES Gregg C. Fonarow Ahmanson-UCLA Cardiomyopathy Center Director; UCLA Division of Cardiology Co-Chief Amgen Janssen Pharmaceuticals Medtronic ZS Pharma None None Medtronic IMPROVE-HF (Steering Committee) Medtronic Daniel D. Matlock University of Colorado School of Medicine Associate Professor of Medicine None None None None None None None Robert J. Myerburg University of Miami Miller School of Medicine Professor of Medicine and Physiology None None None None None None None Richard L. Page University of Wisconsin Hospital and Clinics Chair, Department of Medicine None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. *Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Significant relationship. No financial benefit. ACC indicates American College of Cardiology; AHA, American Heart Association; EP, Electrophysiology; HRS, Heart Rhythm Society; IMPROVE-HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; PI, principal investigator; SUNY, State University of New York; and UT, University of Texas. Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals by Section* CLINICAL STATEMENTS AND GUIDELINES Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (July 2017) Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Salary Expert Witness Alfred E. Buxton Content Reviewer Professor of Medicine Harvard Medical School Beth Israel Deaconess Medical Center None None None NHLBI (DSMB) Medtronic Biosense Webster None None Andrew E. Epstein Content Reviewer Professor of Medicine Cardiovascular Division University of Pennsylvania Chief of Cardiology Section Philadelphia VA Medical Center Zoll* None None Biotronik* Boston Scientific* Boston Scientific (DSMB)* Medtronic* Medtronic (DSMB) St Jude Medical/ Abbott* St Jude Medical/ Abbott (DSMB)* None None Defendant, Amiodarone pulmonary Defendant, Appropriateness of pacemaker implantation, Brian Olshansky Content Reviewer Adjunct Professor of Medicine Des Moines University Professor Emeritus University of Iowa Boehringer Ingleheim Lundbeck Inc* On-X/Cryolife Lundbeck Inc* On-X/Cryolife None Amarin (DSMB)* None None Plaintiff, Long QT sudden Bulent Gorenek Content Reviewer ACC EP Council None None None None None None None Charles I. Berul Content Reviewer Division Chief of Pediatric Cardiology Children s National Medical Center None None None None Circulation* None None Darren Sudman Content Reviewer Executive Director Simon s Fund None None None None None None None George J. Klein Content Reviewer Chief of Cardiology London Health Sciences Center Biotronik Boston Scientific Medtronic* None None None None None None Glenn N. Levine Content Reviewer ACC/ AHA Task Force on Clinical Practice Guidelines Professor of Medicine Baylor College of Medicine Director Cardiac Care Unit Michael E. DeBakey Medical Center None None None None None None Defendant, Catheterization Laboratory Procedure, Defendant, Out of hospital Gurusher S. Panjrath Content Reviewer ACC Heart Failure and Transplant Council Director Heart Failure and Mechanical Support Program George Washington University Amgen Inc.* None None None BEAT-HF ENDEAVOUR None None James P. Daubert Official Reviewer AHA Duke University Medical Center Biosense Webster Boston Scientific CardioFocus Gilead Heart Metabolics Medtronic* St. Jude Medical Zoll None None ARCA biopharma Biosense Webster* Boston Scientific* Gilead* Gilead (DSMB) Medtronic* NHLBI* NHLBI (DSMB) Northwestern University St. Jude Medical (DSMB) VytronUS (DSMB) Biosense* Biotronik* Boston Scientific* Gilead Scienes, Inc.* Medtronic* St. Jude Medical* ACC None James Tisdale Content Reviewer ACC EP Council Professor College of Pharmacy Purdue University Adjunct Professor School of Medicine Indiana University None None None AHA* HRS* Indiana Clinical Translational Sciences Institute/ Strategic Research Initiative* ACC AHA AZCert QT drugs list, credible meds. org None Plaintiff, Drug-induced torsades de pointes, John L. Sapp Official Reviewer HRS Interim Head Division of Cardiology QEII Health Sciences Centre Professor of Medicine Dalhousie University Biosense Webster* Medtronic St. Jude None None Biosense Webster* Canadian Institute of Health Research* DSMB Phillips healthcare* St. Jude Medical* ARTESiA Medtronic Optisure Registry St. Jude None None (Continued) CLINICAL STATEMENTS AND GUIDELINES Joseph Edward Marine Official Reviewer ACC Associate Professor of Medicine Johns Hopkins University School of Medicine None None None None UpToDate None None Kathleen T. Hickey Official Reviewer AHA Professor of Nursing Columbia University Medical Center None None None None None None None Kenneth A. Ellenbogen Content Reviewer Chief of Cardiology Virginia Commonwealth University Medical Center AHA AtriCure* Biosense Webster* Biotronik* Boston Science* Capricor HRS Janssen Medtronic* Pfizer* Sentra heart St. Jude Medical* None None AtriCure* Biosense Webster* Boston Science* Daiichi Sankyo Medtronic* Medtronic (DSMB)* NIH* Pfizer* Biosense Webster* Boston Science* Circulation Heart Rhythm JACC Medtronic* PACE Sanofi Aventis None None Kim K. Birtcher Content Reviewer ACC/ AHA Task Force on Clinical Practice Guidelines University of Houston College of Pharmacology Jones and Bartlett Learning None None None Accreditation Council for Clinical Lipidology University of Houston College of Pharmacology* Walgreens* None Kristen B. Campbell Content Reviewer Duke University Hospital None None None None None None None Kristen K. Patton Content Reviewer Professor of Medicine University of Washington None None None None ABIM ACGME AHA FDA HRS None None L. Brent Mitchell Content Reviewer Professor Department of Cardiac Sciences Libin Cardiovascular Institute of Alberta University of Calgary Alberta Health Services Boehringer Ingelheim* Forest Pharmaceuticals Guidnat Canada* Medtronic Canada* Medtronic Inc* Merck Pfizer* Servier Canada* None None Boston Scientific* ARTESIA Health Protection Branch, Government of Canada None None Martin Borggrefe Content Reviewer I Medizinische KlinikKlinikum Mannheim GmbHUniversit tsklinikum Bayer Health Care Boehringer Ingelheim Impulse Dynamics Sanofi Aventis St. Jude Medical None None German Centre for Cardiovascular Research* None None None Mathew D. Hutchinson Official Reviewer HRS Professor of Medicine University of Arizona College of Medicine Tucson St. Jude Medical None None None None None None Matthew W. Martinez Content Reviewer Sports and Exercise EP Council Lehigh Valley Health Network None None None None None None None Melissa R. Robinson Content Reviewer Director Complex Ablation Program University of Washington Medtronic* Abbott* Boston Scientific* None None None None None None Michael J. Silka Content Reviewer Children s Hospital Los Angeles None None None None None None Defendant, ICD implantation, Miguel A. Quinones Content Reviewer Methodist DeBakey Heart and Vascular Center None None None None Houston Methodist Hospital* None None Mitchell T. Saltzberg Organizational Reviewer HFSA Jefferson Medical College Christiana Care Health System None None Nephroceuticals* Stem Cell Theranostics* None None None None Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Salary Expert Witness (Continued) CLINICAL STATEMENTS AND GUIDELINES N.A. Mark Estes III Content Reviewer Professor of Medicine Tufts University School of Medicine Boston Scientific* Medtronic* St. Jude Medical* None None Boston Scientific* International Board of Heart Rhythm Examiners Medtronic* St. Jude Medical* None None None Norma M. Keller Official Reviewer ACC New York University Medical Center None None None None None None None Peter Leong-Sit Content Reviewer HRS Associate Professor of Medicine Western University London Health Sciences Centre Medtronic Canada Bayer Healthcare Pharmaceuticals Biosense Webster Johnson and Johnson None None None Bayer Healthcare Pharmaceuticals* None Rachel J. Lampert Content Reviewer Yale University School of Medicine Section of Cardiology Medtronic* None None Boston Scientific* GE Medical* Medtronic, Inc.* St. Jude Medical* None None None Sami Viskin Content Reviewer Tel Aviv Medical Center Department of Cardiology Boston Scientific European Strategy Advisory Board None None None None None None Samuel S. Gidding Content Reviewer ACC/ AHA Task Force on Clinical Practice Guidelines Dupont Hospital for Children Nemours Cardiac Center Familial Hypercholesterolemia Foundation Regenxbio None None Familial Hypercholestrolemia Foundation NIH Grants* Cardiology Division Head None None Silvia G. Priori Content Reviewer Professore Ordinario di Cardiologia Universit di Pavia Direttore Scientifico Istituti Clinici Scientifici Maugeri Pavia, Italia Ambry Genetics Boston Scientific Medtronic Medtronic, Inc. None Audentes Therapeutics Inc* Gilead Sciences* HRS None None Susan Strong Official Reviewer AHA Sabin Middle School None None None None None None None Win-Kuang Shen Content Reviewer Professor of Medicine Consultant Mayo Clinic Arizona, Phoenix Campus None None None None None None None Zachary D. Goldberger Official Reviewer ACC/ AHA Task Force on Clinical Practice Guidelines Lead Reviewer Assistant Professor of Medicine Division of Cardiology Harborview Medical Center University of Washington School of Medicine RubiconMD None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. *Significant relationship. No financial benefit. This disclosure was entered under the Clinical Trial Enroller category in the ACC s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees. ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; ACGME, Accreditation Council for Graduate Medical Education; AHA, American Heart Association; ARTESiA, Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; BEAT-HF, Better Effectiveness After Transition Heart Failure DSMB, data safety monitoring board; ENDEAVOUR, carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma; EP, electrophysiology; FDA, US Food and Drug Administration; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; ICD, implantable cardioverter-defibrillator; JACC, Journal of the American College of Cardiology; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; and PACE, Programs of All- Inclusive Care for the Elderly. Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Salary Expert Witness